The biotech company has expanded its clinical trial for a novel cancer drug and prioritized prostate cancer as the primary indication, attracting commercial interest from potential partners.
The biotech company has announced the record date for determining entitlement to new unlisted redeemable non-voting shares, which will carry rights to future commercial benefits from the company's Midkine Investments portfolio.
The biotech company has announced a change in shareholding, with one investor reducing their stake.
The biotech company has announced that its Interim Managing Director has purchased 5 million shares.
The biotech company has secured the exclusive worldwide rights to a novel, clinical-stage cancer therapy, AO-252, through a licensing agreement with Coiled USA and A2A Pharmaceuticals. The transaction is expected to transform the company's pipeline and operations.
The biotech company has agreed to out-license its MK Cell program to Pleiades Pharma for up to $25 million in milestone payments and a royalty stream, providing significant potential upside. The company is also progressing the sale of its Lyramid subsidiary.
The biotech company raises £300,000 through a discounted placing, signaling potential financial difficulties and low investor appetite.
The biotech firm reported continued losses and a significant cash burn as it pivots towards clinical stage assets. A planned acquisition and ongoing trials will require substantial funding, raising concerns about its financial stability.
The biotech company is hosting an investor presentation to provide an update on a proposed acquisition.